Alginate fibre, process for the preparation thereof and use

Details Alginate fibre, process for the preparation thereof and use Alginate fibre, process for the preparation thereof and use

1997-05-30

1999-06-22

Brouillette, D. Gabrielle

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

424445, 424484, 424488, 424DIG13, A61F 1300

Patent

active

059141247

DESCRIPTION:

BRIEF SUMMARY
The present invention relates to alginate fibre, and more particularly to a medicament-impregnated alginate fibre. The invention concerns a fibre from which medicament can be released in a controlled manner, and to the application of this fibre in the preparation of alginate fabrics and wound dressings.
A number of methods for producing conventional alginate fibres are described in the art. The extrusion of alginate solutions into an aqueous solution containing calcium ions to form yarns of calcium alginate filaments is known, for example, from British Patents Nos. 567641, 568177, 571657 and 624987. Such fabrics were generally prepared by knitting a yarn of calcium alginate filaments and partially converting the calcium alginate to the sodium form to form a calcium/sodium alginate containing, for example, 30-70 percent by weight of the carboxyl groups of the alginate in the calcium form.
The use of alginate fibres in the preparation of wound dressings which may incorporate certain medicaments is also known in the art. For example, EP-A-0279118 describes an adhesive product suitable for use on wounds comprising a backing layer of a moisture vapour transmitting continuous polymer film and a layer of a pressure sensitive adhesive containing inter alia at least 30% by weight of alginate. The adhesive product described therein can contain a medicament, such as a chlorhexidine derivative, normally in the adhesive layer. Alternatively, the medicament may form part of the alginate polymer used for the pressure sensitive adhesive layer, suitable examples being stated to include silver, copper and zinc derivatives of sodium alginate.
Additionally, U.S. Pat. No. 4,753,231 discloses the incorporation of such antibacterial agents as silver sulphadiazine, povidone-iodine, chlorhexidine salts such as gluconate, acetate and hydrochloride, and quaternary agents such as benzalkonium chloride into a wound dressing pad.
Moreover, U.S. Pat. No. 4,817,594 discloses wound dressings as supports for therapeutic or antiseptic materials including iodine, formol, lime, oxygen, bacillary toxins and the like.
The commercially available products Bactigras and Serotulle, obtainable respectively from Smith and Nephew Ltd., Hull, United Kingdom, and Seton Healthcare Group, Oldham, United Kingdom, both consist of paraffin gauze impregnated with the antibacterial agent chlorhexidine.
The abovedescribed medicated wound dressings of the prior art comprise medicaments absorbed onto the surface of the fibres making up the wound dressing. The use of such wound dressings is somewhat restricted by the amount of medicament which can be incorporated onto the surface of the alginate fibre, and furthermore by the fact that such surface-bound medicaments are expected to be released rapidly in the environment of use. For a variety of clinical applications, it is considered desirable to provide a controlled release of the same or a different medicament to a wound over time. If the medicament were merely applied topically throughout the treatment regimen, this would require frequent removal and replacement of the dressing, with concomitant inconvenience and risk of opportunistic infection.
WO 94/00164 describes an alginate fibre comprising one or more medicaments incorporated into the fibre core such that the or each medicament can be released in a sustained manner over time, and optionally one or more medicaments which can be attached to the surface of the fibre for rapid release therefrom. The amount of medicament which can be incorporated onto the surface and/or into the core is respectively 0.01% to 2.0% by weight.
We have now developed alginate fibres which allow increased incorporation of one or more medicaments into the structure thereof, the medicament thereby being suitable for sustained release from the alginate fibre.
According to the present invention there is provided alginate fibre comprising at least one medicament incorporated into the structure thereof, the medicament being present at a level of at least 10% by weight, based on the weight

REFERENCES:
patent: 5690955 (1997-11-01), Griffiths

Affiliated with

Also associated with

Rating

Alginate fibre, process for the preparation thereof and use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alginate fibre, process for the preparation thereof and use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alginate fibre, process for the preparation thereof and use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1706977